•  
  •  
  •  
  •  

2026-07-22 05:25:40

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • CRISIL Limited Reports Q2 CY26 / Q1 FY27 Results: Consolidated Revenue Jumps 27.6% YoY to ₹1,075.39 Crore; Net Profit Reaches ₹216.46 Crore
  • Purple Finance Grants In-Principle Approval to Acquire 100% Stake in Saksham Gram Credit
  • InfoBeans Technologies Reports Q1 FY27 Results: Revenue Jumps 36.6% YoY to ₹152.77 Crore; Net Profit Stands at ₹21.62 Crore
  • Gamco Limited Reports Q1 FY27 Results: Consolidated Revenue Surges 105.8% YoY to ₹113.72 Crore; PAT Reaches ₹32.43 Crore
  • Gabriel India Reports Q1 FY27 Results: Consolidated Revenue Up 15.5% YoY to ₹1,425.68 Crore; Net Profit Reaches ₹108.13 Crore

Keywords Selected:  Form483

Stock Report

  • Wanbury Limited gets 6 observations from USFDA after cGMP inspection at Tanuku facility
  • US FDA Inspection at Alkem Laboratories Ltd's manufacturing facility located at Amaliya, Daman
  • USFDA inspection at Somerset facility of Lupin Ltd
  • Granules India Limited completes cGMP Audit at its Chantilly Site
  • Unit-IV of APL Healthcare Ltd classified as VAI by the US FDA
  • Strides Pharma Inc's Chestnut Ridge facility gets 4 observations from USFDA
  • APL Healthcare Ltd's Unit-4 gets 5 observations from USFDA
  • Apitoria Pharma Pvt Ltd receives 3 observations from USFDA for Unit-V
  • Shilpa Medicare Ltd receives 8 observations from USFDA for Unit 4 at Jadcherla
  • Lupin Ltd receives 7 observations from USFDA for Goa manufacturing facility
  • Apitoria Pharma Pvt Ltd receives 5 observations from USFDA for API facility
  • Lupin receives Form 483 with 3 observations from USFDA for Pithampur Unit-3
  • Lupin receives Form 483 with 4 observations from USFDA for Pithampur Unit-2
  • Granules India Ltd receives 1 observation from USFDA for Chantilly facility
  • Unichem Laboratories Ltd receives Form 483 from USFDA with 3 observations for Roha API facility
  • Granules India Ltd receives Form 483 with 1 observation from USFDA for Bonthapally API unit 1
  • U.S. FDA inspection at Glenmark Pharma's Facility at Monroe, North Carolina, USA
  • Sun Pharma gets 8 observations from USFDA for Halol facility
  • Neuland Laboratories Ltd completes USFDA inspection at Unit 2
  • USFDA Inspection at Concord Biotech Ltd's API facility at Dholka
  • J B Chemicals & Pharmaceuticals Ltd successfully completes USFDA inspection at API facility
  • Indoco's Clinical Research Organisation - AnaCipher completes US FDA inspection
  • USFDA Inspection at Unit-1 of Shilpa Pharma Lifesciences Limited
  • USFDA inspection at Emcure Pharmaceuticals Ltd's API facility

Latest Post

  • CRISIL Limited Reports Q2 CY26 / Q1 FY27 Results: Consolidated Revenue Jumps 27.6% YoY to ₹1,075.39 Crore; Net Profit Reaches ₹216.46 Crore
  • Purple Finance Grants In-Principle Approval to Acquire 100% Stake in Saksham Gram Credit
  • InfoBeans Technologies Reports Q1 FY27 Results: Revenue Jumps 36.6% YoY to ₹152.77 Crore; Net Profit Stands at ₹21.62 Crore
  • Gamco Limited Reports Q1 FY27 Results: Consolidated Revenue Surges 105.8% YoY to ₹113.72 Crore; PAT Reaches ₹32.43 Crore
  • Gabriel India Reports Q1 FY27 Results: Consolidated Revenue Up 15.5% YoY to ₹1,425.68 Crore; Net Profit Reaches ₹108.13 Crore


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025